Related Experiment Videos
Active immunization against hepatitis A in dialysis patients
Erwin Hermann Fleischmann1, Johannes Kruppenbacher, Hans Ludwig Bock
1Medizinische Klinik IV der Universität Erlangen Nürnberg, Virologisches Institut der Universität zu Köln, Germany.
Summary
Hepatitis A vaccination is safe and effective for patients with end-stage renal failure on chronic intermittent hemodialysis. The vaccine is well-tolerated and produces a strong immune response, supporting its use in this vulnerable population.
Area of Science:
- Nephrology
- Immunology
- Vaccinology
Background:
- End-stage renal failure (ESRF) patients on chronic intermittent hemodialysis are at increased risk for infectious diseases.
- Hepatitis A virus (HAV) infection poses a significant threat to immunocompromised individuals.
Purpose of the Study:
- To assess the feasibility, immunogenicity, and reactogenicity of hepatitis A vaccination in ESRF patients undergoing hemodialysis.
- To compare intramuscular versus subcutaneous administration of the inactivated hepatitis A vaccine.
Main Methods:
- Forty-three ESRF patients on hemodialysis received an inactivated hepatitis A vaccine on a 0-, 1-, and 6-month schedule.
- Participants were divided into two groups: intramuscular (n=30) and subcutaneous (n=13) vaccination.
Main Results:
- High antibody response against hepatitis A was observed in 100% of the intramuscular group and 92% of the subcutaneous group.
- Geometric mean titres (GMT) were comparable to those in healthy individuals, with a trend towards higher GMT with subcutaneous administration.
- No significant adverse events or liver enzyme abnormalities were recorded.
Conclusions:
- Hepatitis A vaccination is feasible, well-tolerated, and immunogenic in dialysis patients.
- Subcutaneous administration is a viable alternative for patients with contraindications to intramuscular injection.